Bio View

Bio View Receivables/Revenue

The Receivables to Revenue Ratio of Bio View (BIOV.TA) as of Nov 4, 2026 is 18.17 %. In the previous year, Receivables to Revenue Ratio was 21.31 % — a change of -14.72% (lower).

Receivables/Revenue

18.17 %

YoY

-14.72%

Last updated:

Receivables to Revenue Ratio of Bio View is 2024 18.17 % . Receivables to Revenue Ratio of Bio View was 2023 21.31 % . It decreases by -14.72% lower compared to the previous year.

The Bio View Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2017
16.96 ILS
Jan 1, 2018
12.12 ILS
Jan 1, 2019
12.02 ILS
Jan 1, 2020
12.42 ILS
Jan 1, 2021
14.48 ILS
Jan 1, 2022
18.13 ILS
Jan 1, 2023
21.31 ILS
Jan 1, 2024
18.17 ILS
The Bio View Receivables/Revenue history
YEARReceivables/RevenueYoY
18.17 %-14.72%
21.31 %+17.50%
18.13 %+25.24%
14.48 %+16.62%
12.42 %+3.31%
12.02 %-0.82%
12.12 %-28.57%
16.96 %+21.46%
13.97 %+59.12%
8.78 %-47.60%
16.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio View Stock analysis

What does Bio View do? BioView Ltd. generates revenue through the sale and servicing of its Duet automated cell diagnostic system, designed for use in cytology, cytogenetic, hematology, and pathology laboratories. The Duet system enables automated detection, classification, analysis, and counting of cells, offering unique capabilities in analyzing both cell morphology and genetic content simultaneously. Additional products include the ALLEGRO workstation for automated scanning of FISH probes without Brightfield scanning and the ACCORD workstation for semi-automated imaging of FISH in breast cancer (Her-2/Neu) analysis and FISH on tissue. These systems target medical professionals in cancer diagnosis, minimal-residual disease monitoring, prenatal and postnatal cytogenetic analyses, sperm cell studies, and rare-cell detection. The company's primary customers are laboratories specializing in cytology, cytogenetics, hematology, and pathology, including those focused on cancer diagnostics and genetic analysis. These institutions purchase the Duet system for routine diagnostic workflows and the ALLEGRO and ACCORD workstations for specialized applications such as FISH analysis in breast cancer and genetic studies. BioView Ltd. also provides ongoing servicing and support for its systems, contributing to recurring revenue streams. BioView Ltd. markets its products under the brand names Duet, ALLEGRO, and ACCORD, with the Duet system serving as the core offering for general cell analysis. The ALLEGRO and ACCORD workstations cater to niche applications in FISH-based diagnostics, particularly in oncology and genetic testing. The company's revenue is derived from direct sales of these systems to healthcare facilities and laboratories, with no mention of third-party partnerships or additional revenue streams beyond product sales and servicing. Bio View is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio View stock

Receivables to Revenue Ratio of Bio View is 18.17 % in 2024.

Receivables to Revenue Ratio of Bio View changed from 21.31 % to 18.17 %, representing a -14.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio Bio View since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's Bio View with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio View

All Key Metrics — Bio View